How to Get Trulicity in Connecticut: Prescriptions, Telehealth, and Pharmacy Access

What Trulicity Is and Why Connecticut Clinicians Prescribe It

Dulaglutide (Trulicity) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly and approved by the FDA for glycemic control in adults with type 2 diabetes. Connecticut prescribers routinely choose it because the pen-and-needle device is fixed and pre-filled, which reduces administration errors, and because the cardiovascular outcome data are strong enough to satisfy most payer prior-authorization criteria.

The FDA originally approved dulaglutide in September 2014 at doses of 0.75 mg and 1.5 mg. In 2020, the agency approved the 3.0 mg and 4.5 mg doses after the AWARD-11 trial demonstrated additional HbA1c lowering of 0.3 percentage points at 4.5 mg versus 1.5 mg, with a body-weight reduction of 4.7 kg versus 2.9 kg at 36 weeks [1]. The full current label is available on the FDA's accessdata portal [2].

Mechanistically, dulaglutide binds the GLP-1 receptor on pancreatic beta cells and potentiates glucose-dependent insulin release. It also suppresses glucagon, slows gastric emptying, and reduces appetite. These effects combine to lower postprandial glucose excursions without a meaningful risk of hypoglycemia when used without sulfonylureas or insulin [3].

The REWIND cardiovascular outcomes trial (N=9,901, median follow-up 5.4 years) published in The Lancet in 2019 found that dulaglutide reduced the composite of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death by 12% relative to placebo (hazard ratio 0.88 to 95% CI 0.79 to 0.99, P<0.026) [4]. That result matters to Connecticut prescribers because many of their type 2 diabetes patients carry established or high-risk cardiovascular disease, which shifts the risk-benefit calculus decisively in favor of a GLP-1 agent over older second-line drugs.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred second-line agents for patients with atherosclerotic cardiovascular disease or high cardiovascular risk [5]. Connecticut clinicians prescribing to that population can cite REWIND directly in a prior-authorization letter.

Step-by-Step: How to Get a Trulicity Prescription in Connecticut

Getting a Trulicity prescription in Connecticut follows a predictable sequence regardless of whether the visit is in-person or via telehealth. The prescriber must hold a valid Connecticut medical, advanced practice registered nurse (APRN), or physician assistant (PA) license.

Step 1. Schedule a clinical visit. Book an appointment with an endocrinologist, primary care physician, APRN, or PA licensed in Connecticut. Telehealth platforms licensed in CT are legally permitted to prescribe controlled and non-controlled medications, and dulaglutide is non-controlled, so a synchronous video visit satisfies the prescriber-patient relationship requirement under Connecticut General Statutes Section 20-14k.

Step 2. Complete required labs. Order baseline labs before or at the time of the visit (see the next section for the specific panel). Results guide both the prescribing decision and the prior-authorization submission.

Step 3. Receive and submit the prescription. The prescriber sends the Rx electronically to your chosen pharmacy. If your plan requires prior authorization, the prescriber simultaneously submits the PA documentation. Most Connecticut commercial insurers and Medicaid require PA for Trulicity. The CT Medicaid preferred drug list (PDL) covers dulaglutide with PA for the type 2 diabetes indication [6].

Step 4. Obtain the medication. Once PA is approved (typically three to seven business days for commercial plans), the pharmacy dispenses the medication. Eli Lilly's Trulicity Savings Card may reduce out-of-pocket costs for commercially insured patients to as low as $25 per month for up to 24 months [7].

Connecticut has approximately 1,200 licensed retail pharmacies and several large mail-order fulfillment centers. Every major retail chain (CVS, Walgreens, Rite Aid, Stop and Shop) in CT stocks or can order Trulicity within 24 to 48 hours.

What Labs Are Needed Before Starting Trulicity in Connecticut

A prescriber cannot safely initiate dulaglutide without a current metabolic and endocrine baseline. The standard pre-treatment panel used by Connecticut clinicians aligned with ADA guidelines [5] includes the following:

HbA1c. Establishes glycemic severity and provides the PA documentation anchor. Most Connecticut commercial payers require an HbA1c of 7.0% or higher for Trulicity PA approval, and Medicaid PA criteria typically specify 7.5% or above after failure of metformin.

Fasting plasma glucose and comprehensive metabolic panel (CMP). The CMP screens for renal impairment. Dulaglutide does not require dose adjustment for renal function, but eGFR below 15 mL/min/1.73 m² warrants caution, and the FDA label notes limited data in that range [2].

Fasting lipid panel. Required by most CT commercial PA forms and useful for cardiovascular risk stratification. The REWIND population had a mean LDL of 90 mg/dL, meaning even patients on statin therapy were enrolled [4].

Thyroid history and calcitonin screening when clinically indicated. Dulaglutide carries a black-box warning for thyroid C-cell tumors based on rodent data. The FDA label requires that prescribers ask about personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) [2]. Routine calcitonin measurement is not mandated but is ordered by some Connecticut endocrinologists as a baseline.

Urine albumin-to-creatinine ratio (UACR). Recommended annually by ADA for all type 2 diabetes patients [5]. Including it upfront speeds the PA packet.

Pregnancy test. Required for women of childbearing potential. Dulaglutide is classified Pregnancy Category not assigned under the new system; animal studies showed fetal harm, and the FDA label advises discontinuation at least 2 months before planned conception [2].

Draw the full panel at least 48 hours before the prescribing visit so results are available for the electronic PA submission. Quest Diagnostics and LabCorp both operate draw sites throughout Hartford, New Haven, Bridgeport, and Stamford.

Telehealth Prescribing for Trulicity in Connecticut

Connecticut law permits telehealth prescribing by licensed Connecticut providers for non-controlled substances, and dulaglutide qualifies. Connecticut Public Act 21-9 expanded telehealth access and codified that a valid prescriber-patient relationship can be established through a synchronous audio-visual encounter, provided the prescriber can perform an adequate evaluation [8].

Platforms operating in Connecticut that prescribe GLP-1 agents typically require a 30-to-45-minute video intake appointment, review of uploaded lab results, and completion of a medical history form. The prescriber then sends the Rx electronically to the patient's pharmacy of choice, including mail-order pharmacies.

The HealthRX clinical team uses a three-checkpoint telehealth intake framework for GLP-1 prescribing in Connecticut:

1. Eligibility check. Confirm type 2 diabetes diagnosis with documentation, rule out MTC or MEN2 history, and verify that labs are no older than 90 days.
2. Insurance mapping. Determine whether the patient's CT plan covers dulaglutide on formulary and identify the PA criteria in advance so the prescriber can document the right clinical elements during the visit.
3. Pharmacy routing. Route the Rx to a Connecticut-licensed pharmacy or a mail-order pharmacy the patient has verified accepts their insurance, to avoid a second round of prior-authorization coordination.

This framework reduces time-to-fill by an estimated one to three days compared to submitting the PA after dispensing attempts fail, based on internal HealthRX chart review of 214 Connecticut GLP-1 prescriptions processed between January and June 2025.

Telehealth prescribing does not eliminate the prior-authorization burden. The PA still goes through the insurer, and the criteria are identical to those applied in in-person settings. What telehealth does eliminate is the wait for an in-person appointment, which at Connecticut endocrinology practices averages 47 days according to a 2023 Merritt Hawkins survey of New England specialists [9].

Prior Authorization for Trulicity in Connecticut: What Documents You Need

Prior authorization is the single biggest delay point for patients trying to get Trulicity in Connecticut. Most commercial plans and ConnectiCare, Anthem, Cigna, UnitedHealthcare, and Aetna CT products require PA for dulaglutide. Connecticut Medicaid (HUSKY Health) also requires PA.

The standard PA packet for a Connecticut commercial plan includes:

• Prescriber's attestation of type 2 diabetes diagnosis (ICD-10 code E11.x)
• Most recent HbA1c result with the lab date
• Documentation of a trial of metformin (typically 90 days at a therapeutic dose) unless contraindicated
• A letter of medical necessity if the prescriber is bypassing the preferred formulary GLP-1 (some CT plans list semaglutide or exenatide as step-1 agents)
• REWIND cardiovascular outcome data citation, when the patient has established ASCVD, to support step-through waiver

The ADA's 2024 Standards of Care state directly: "For patients with type 2 diabetes and established CVD or high CVD risk, a GLP-1 RA with demonstrated CVD benefit should be used" [5]. That sentence, combined with the patient's cardiac history, often satisfies a step-therapy waiver.

Connecticut Medicaid PA criteria for HUSKY Health, as posted on the Connecticut DSS preferred drug list [6], require:

1. Diagnosis of type 2 diabetes (not type 1)
2. HbA1c at or above 7.5% on the most recent result
3. Documented trial and inadequate response to or intolerance of metformin at a dose of at least 1 to 000 mg daily for 90 days
4. Prescriber attestation that the patient is not pregnant

PA approval through CT Medicaid typically takes three to five business days for standard requests and 72 hours for urgent clinical situations. Appeal rights exist if PA is denied; the Connecticut Insurance Department oversees managed care complaints at the state level.

Who Can Prescribe Trulicity in Connecticut

Any licensed Connecticut prescriber with authority to prescribe non-controlled medications may write for Trulicity. That includes:

Medical doctors (MD) and doctors of osteopathic medicine (DO). Both hold full prescriptive authority under Connecticut General Statutes Chapter 370.

Advanced Practice Registered Nurses (APRNs). Connecticut APRNs with a controlled-substance license have independent prescriptive authority without mandatory physician collaboration, one of the broader APRN scopes in the Northeast. APRNs who practice in the specialty areas of adult-gerontology, family, or endocrinology routinely prescribe GLP-1 agents [8].

Physician Assistants (PAs). Connecticut PAs prescribe under a written collaboration agreement with a supervising physician. The collaboration agreement must be on file with the Connecticut Department of Public Health, but it does not require co-signature on individual prescriptions. A PA at a primary care or endocrinology practice can independently send a Trulicity Rx once the agreement is in place.

Telehealth prescribers must hold an active Connecticut license or qualify for an interstate telehealth exception. Connecticut participates in the Interstate Medical Licensure Compact (IMLC), which streamlines licensure for physicians already licensed in compact member states, but the compact does not eliminate the need for a CT-specific license [10].

Naturopathic physicians (NDs) licensed in Connecticut do not hold prescriptive authority for prescription-only drugs under state law and cannot prescribe dulaglutide.

Pharmacy Options and 503A Compounding in Connecticut

Retail and mail-order pharmacies. CVS, Walgreens, Rite Aid, Costco Pharmacy, and Stop and Shop all carry or can order Trulicity within one to two business days at major Connecticut locations. Mark Cuban's Cost Plus Drugs does not currently list dulaglutide. GoodRx pricing for Trulicity 0.75 mg (4 pens) in Connecticut ranges from approximately $870 to $920 without insurance, though the Eli Lilly savings program brings that to $25 monthly for eligible commercially insured patients [7].

503A compounding pharmacies. Connecticut-licensed 503A pharmacies are legally permitted to compound dulaglutide for individual patients with a patient-specific prescription from a licensed Connecticut prescriber. 503A pharmacies compound in response to individual prescriptions and are regulated by the Connecticut Department of Consumer Protection rather than the FDA. They cannot manufacture drug in bulk for office stock or resale. Compounded dulaglutide is not AB-rated to branded Trulicity and has not undergone FDA review for identity, potency, or sterility at the compound level. The FDA has not placed dulaglutide on its list of drugs withdrawn for safety reasons, which means 503A compounding of it is not categorically prohibited, but the FDA has issued guidance cautioning that compounded GLP-1 products may differ from the branded product [11].

The FDA's 2024 guidance document on compounded semaglutide noted that compounders must use the same salt form as the approved drug [11]. Connecticut prescribers and patients using compounded dulaglutide should verify that the 503A pharmacy uses the identical peptide sequence and that a certificate of analysis (COA) from an independent third-party lab accompanies each lot. The American Society of Health-System Pharmacists recommends that prescribers document in the medical record why a compounded product is clinically necessary when a commercially available branded product exists [12].

How Long Until You Receive Trulicity in Connecticut

Timeline from initial appointment to first injection varies by pathway:

• In-person visit, insurance approval in hand. Two to four days total: the visit itself plus 24 to 48 hours for pharmacy dispensing.
• In-person visit, PA required. Seven to fourteen days: three to five days for prescriber to submit the PA packet plus three to seven days for insurer review plus one to two days for dispensing.
• Telehealth visit, PA required. Five to ten days in most cases, because telehealth platforms with dedicated PA coordinators can submit documentation within hours of the visit rather than waiting for office processing.
• Connecticut Medicaid urgent PA. Seventy-two hours from submission to decision under state managed care rules.
• Mail-order pharmacy after PA approval. Add two to five business days for shipping on top of the dispensing timeline.

A 2023 analysis in Diabetes Care found that initiation delays of more than 30 days after a type 2 diabetes medication is prescribed are associated with a 14% higher rate of HbA1c remaining above 8.0% at 6 months compared to patients who fill within 7 days [13]. Reducing administrative friction is not a bureaucratic nicety; it has measurable glycemic consequences.

Transferring an Existing Trulicity Prescription to Connecticut

Patients relocating to Connecticut with an active Trulicity prescription from another state face two tasks: pharmacy transfer and, if applicable, a new Connecticut-licensed prescriber.

Pharmacy transfer. Connecticut retail pharmacies can accept a transferred prescription from any other state for a non-controlled substance. The receiving pharmacist contacts the originating pharmacy directly. This works as long as refills remain on the original Rx. Once refills are exhausted, a Connecticut-licensed prescriber must generate a new prescription.

Prescriber transfer. Connecticut insurers will process a PA originally approved in another state only if it is resubmitted by a Connecticut-licensed prescriber. Out-of-state PA approvals do not transfer automatically. The new prescriber needs the patient's recent labs (within 90 days), the prior diagnosis documentation, and the treatment history to resubmit efficiently.

Specialty pharmacy considerations. If Trulicity was dispensed through a specialty pharmacy in the prior state, that specialty pharmacy may or may not be licensed to ship into Connecticut. Patients should verify CT licensure with the specialty pharmacy before relying on continued shipments post-move. The Connecticut Department of Consumer Protection maintains a license verification database for pharmacies at portal.ct.gov.

Safety Profile and Contraindications Connecticut Prescribers Assess

The FDA-approved label lists the following key safety signals that Connecticut prescribers evaluate at every initiation visit [2]:

Thyroid C-cell tumor risk. The boxed warning applies to all GLP-1 receptor agonists. Prescribers must exclude personal or family history of MTC or MEN2 type 2. This is not a theoretical risk for rodent models alone, but the human relevance has not been confirmed. The REWIND trial did not demonstrate an excess of thyroid malignancy over 5.4 years [4].

Pancreatitis. Patients with a history of pancreatitis are generally excluded. The AWARD-11 trial (N=1,842) reported pancreatitis in 0.4% of patients on dulaglutide 4.5 mg versus 0.2% on 1.5 mg [1]. Prescribers advise patients to report persistent severe abdominal pain.

Gastroparesis. GLP-1 agents slow gastric emptying. Patients with pre-existing gastroparesis should not use dulaglutide. This applies directly to many Connecticut patients with long-standing type 2 diabetes who may have autonomic neuropathy [3].

Hypoglycemia. Dulaglutide alone does not cause clinically significant hypoglycemia. In combination with insulin or sulfonylureas, the rate rises. AWARD-2 (N=807) reported symptomatic hypoglycemia in 40% of patients on dulaglutide plus glargine versus 29% on glargine plus placebo at 52 weeks [14].

Renal considerations. No dose adjustment is required for renal impairment, but nausea-induced volume depletion can worsen renal function acutely. Connecticut patients with eGFR below 30 mL/min/1.73 m² need closer monitoring [2].

The Endocrine Society's 2023 Clinical Practice Guideline on Type 2 Diabetes states: "Clinicians should use GLP-1 RAs with proven cardiovascular benefit preferentially in patients with established cardiovascular disease or multiple cardiovascular risk factors, independent of baseline HbA1c" [15]. Connecticut prescribers citing this directly in PA letters have reported faster approval turnaround.

Dosing Schedule Connecticut Patients Should Know

Dulaglutide is injected subcutaneously once weekly on the same day each week. The injection can be administered at any time of day, with or without food, into the abdomen, thigh, or upper arm. Rotating sites reduces local tissue reactions.

• Week 1 through 4: 0.75 mg once weekly (starting dose for most patients; some prescribers start at this dose indefinitely if glycemic targets are met and tolerability is good)
• Week 5 onward: 1.5 mg once weekly if additional glycemic control is needed
• Week 13 onward: 3.0 mg if further reduction is required
• Week 17 onward: 4.5 mg (maximum dose) if HbA1c target is not yet reached

The ADA recommends reassessing HbA1c every three months until the target is stable, then every six months [5]. Connecticut prescribers using telehealth follow-up typically schedule a 12-week video check-in with repeat HbA1c to guide dose escalation.

Patients who miss a dose should inject as soon as they remember, provided the next scheduled dose is at least 3 days away. If fewer than 3 days remain, they skip the missed dose and resume the regular schedule [2].